Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-TNBC
NCT02688803Phase 4Terminated
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxorubicin, cyclophosphamide, paclitaxel, fluorouracil, epirubicin and 1 more in triple-negative breast cancer (TNBC) (3 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoints: Percentage of Patients Who Receive Chemotherapy in the Neoadjuvant/Adjuvant Setting for TNBC at 1 year and Participant Satisfaction at 1 year. Started Aug 2016; status: terminated.
02
Drugs
doxorubicincyclophosphamidepaclitaxelfluorouracilepirubicin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02688803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688803.